Results 1 to 10 of about 2,662 (106)

How glucagon-like peptide 1 receptor agonists work [PDF]

Endocrine Connections, 2021
In recent years, glucagon-like peptide 1 receptor agonists (GLP-1RAs) have become central in the treatment of type 2 diabetes (T2D). In addition to their glucose-lowering properties with low risk of hypoglycaemia, GLP-1RAs reduce body weight and show ...
Christine Rode Andreasen, Andreas Andersen, Filip Krag Knop, Tina Vilsbøll   +3 more
doaj   +4 more sources

Glucagon-like peptide-1 receptor agonists in orthopaedics

SICOT-J
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RA) help people control blood glucose and lose weight. They may also help with bone metabolism, healing fractures, keeping joints healthy, and recovering after surgery.
Mavrogenis Andreas F., Altsitzioglou Pavlos, Pililis Sotirios, Anastasilakis Athanasios D., Tournis Symeon, Makras Polyzois, Saranteas Theodosis, Lustig Sebastien   +7 more
doaj   +4 more sources

Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists [PDF]

Endocrinology and Metabolism, 2016
Glucagon-like peptide-1 (GLP-1) is a member of the proglucagon incretin family, and GLP-1 receptor agonists (RAs) have been introduced as a new class of antidiabetic medications in the past decade.
Yu Mi Kang, Chang Hee Jung
doaj   +3 more sources

Glucagon-like peptide-1 receptor agonists in neoplastic diseases

Frontiers in Endocrinology
Glucagon-like peptide-1 receptor agonist (GLP-1RA), a novel hypoglycemic agent for the treatment of type 2 diabetes, has well-known effects such as lowering blood sugar, ameliorating inflammation, reducing weight, and lowering blood lipids.
Lisan Ji, Xianzhen He, Xinwen Min, Handong Yang, Wenwen Wu, Hao Xu, Jun Chen, Jun Chen, Aihua Mei   +8 more
doaj   +3 more sources

History of glucagon-like peptide-1 receptor agonists

Pharmacological Research
Radwan Darwish, Ghena Abu-Sharia, Alexandra E. Butler   +2 more
doaj   +3 more sources

Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis

Frontiers in Endocrinology, 2021
ObjectiveNon-alcoholic fatty liver disease is highly prevalent in patients with type 2 diabetes mellitus. Studies on glucagon-like peptide-1 receptor agonists for the treatment of non-alcoholic fatty liver disease have reported promising results. Despite
Chloe Wong, Ming Hui Lee, Clyve Yu Leon Yaow, Yip Han Chin, Xin Lei Goh, Cheng Han Ng, Amanda Yuan Ling Lim, Amanda Yuan Ling Lim, Mark Dhinesh Muthiah, Mark Dhinesh Muthiah, Mark Dhinesh Muthiah, Chin Meng Khoo, Chin Meng Khoo   +12 more
doaj   +1 more source

Systemic GLP-1R agonist treatment reverses mouse glial and neurovascular cell transcriptomic aging signatures in a genome-wide manner

Communications Biology, 2021
Li, Chen, Vong, Zhao et al. show that glucagon-like peptide-1 receptor agonist reverses transcriptomic aging signatures in mouse glial and neurovascular cells.
Zhongqi Li, Xinyi Chen, Joaquim S. L. Vong, Lei Zhao, Junzhe Huang, Leo Y. C. Yan, Bonaventure Ip, Yun Kwok Wing, Hei-Ming Lai, Vincent C. T. Mok, Ho Ko   +10 more
doaj   +1 more source

Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 agonists as potential neuroprotective agents

Neural Regeneration Research, 2019
Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 receptor agonists is a breakthrough in the field of neural regeneration research increasing glucagon like peptide-1 bioavailability, hence its neuroprotective activities.
Shaker A Mousa, Bassam M Ayoub
doaj   +1 more source

The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis.

PLoS ONE, 2015
AimsTo determine the effects of glucagon-like peptide-1 receptor agonists compared with placebo and other anti-diabetic agents on weight loss in overweight or obese patients with type 2 diabetes mellitus.MethodsElectronic searches were conducted for ...
Jessica E Potts, Laura J Gray, Emer M Brady, Kamlesh Khunti, Melanie J Davies, Danielle H Bodicoat   +5 more
doaj   +1 more source

Nephroprotective potential of glucagon-like peptide-1 receptor agonists

Сахарный диабет, 2020
Patients with diabetes mellitus (DM), which is a key factor in the development of kidney diseases, are increasingly competing for limited healthcare resources.
Minara S. Shamkhalova, Igor A. Sklyanik, Marina V. Shestakova   +2 more
doaj   +1 more source